Exicure’s CEO David Giljohann Honored in Crain’s 40 Under 40 Class of 2019
November 13 2019 - 9:00AM
Business Wire
Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and
immunotherapeutic drugs utilizing spherical nucleic acid (SNA™)
technology, today announced that David Giljohann, chief executive
officer Exicure, Inc. (Nasdaq: XCUR), has been named to Crain’s
Chicago Business magazine’s 2019 Class of “40 Under 40.”
Crain’s “40 Under 40” recognizes individuals who are reinventing
what it means to do business in Chicago through financial impact
and community leadership. Dr. Giljohann, along with the other
honorees, will be profiled in the November 18 issues of Crain’s
Chicago Business.
“It is truly an honor to be recognized for my work at Exicure,
which has always been driven by my personal goal of positively
impacting patients by creating revolutionary new medicines,” says
Giljohann. “I am thankful for the support and dedication of the
entire Exicure team that is working tirelessly on our programs to
address unmet medical needs in genetic disorders, inflammatory
disease and oncology.”
Dr. Giljohann has served as Chief Executive Officer of Exicure
since November 2013, after starting out as the company’s founding
scientist in 2011. He completed his Ph.D. in 2009 in the laboratory
of Dr. Chad A. Mirkin at Northwestern University where he developed
oligonucleotide-modified nanoparticles, including Exicure’s
Spherical Nucleic Acid (SNA™) constructs. Dr. Giljohann has been on
the Company’s Board of Directors since March 2014.
Dr. Giljohann’s work has been recognized with a Materials
Research Society Gold Award, Baxter Innovation Award, Rappaport
Award for Research Excellence, NSEC Outstanding Research Award, and
as a finalist in the National Inventors Hall of Fame Collegiate
Inventors Competition. Additionally, Dr. Giljohann has contributed
to over 100 patents and applications.
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company
developing therapeutics for immuno-oncology, inflammatory diseases
and genetic disorders based on our proprietary Spherical Nucleic
Acid, or SNA technology. Exicure believes that its proprietary SNA
architecture has distinct chemical and biological properties that
may provide advantages over other nucleic acid therapeutics and may
have therapeutic potential to target diseases not typically
addressed with other nucleic acid therapeutics. Exicure's lead
program is in a Phase 1b/2 trial in patients with advanced solid
tumors. Exicure is based outside of Chicago, IL and in Cambridge,
MA. www.exicuretx.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191113005038/en/
MacDougall Karen Sharma 781-235-3060 ksharma@macbiocom.com
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jul 2023 to Jul 2024